These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 18075282

  • 21. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
    Espino A, Villagrán A, Vollrath V, Hanckes P, Salas R, Farah A, Solís N, Pizarro M, Escalona A, Boza C, Pérez G, Carrasco G, Padilla O, Miquel JF, Nervi F, Chavez-Tapia NC, Arab JP, Alvarez-Lobos M, Arrese M, Riquelme A.
    Ann Hepatol; 2011; 10(4):493-501. PubMed ID: 21911891
    [Abstract] [Full Text] [Related]

  • 22. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
    Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, Ersoz HO.
    Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
    [Abstract] [Full Text] [Related]

  • 23. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.
    Lau HK, Segev A, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH.
    Thromb Haemost; 2003 Dec; 90(6):1187-91. PubMed ID: 14652655
    [Abstract] [Full Text] [Related]

  • 24. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
    Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A.
    J Thromb Haemost; 2012 Dec; 10(12):2555-62. PubMed ID: 23083123
    [Abstract] [Full Text] [Related]

  • 25. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 26. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
    Akinci B, Demir T, Saygili S, Yener S, Alacacioglu I, Saygili F, Bayraktar F, Yesil S.
    Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
    [Abstract] [Full Text] [Related]

  • 27. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 28. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.
    Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y.
    J Clin Endocrinol Metab; 2002 Feb 01; 87(2):660-5. PubMed ID: 11836301
    [Abstract] [Full Text] [Related]

  • 29. Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
    Wada H, Nobori T, Watanabe R, Shiku H, Sakuragawa N.
    Turk J Haematol; 2002 Jun 05; 19(2):235-7. PubMed ID: 27264764
    [Abstract] [Full Text] [Related]

  • 30. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Jun 05; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 31. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 32. [Study of fibrinolysis inhibitors in 117 acute leukemia patients].
    Wang W, Ji CY, Ye JJ, Zhu YY, Guo DM, Ji M.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Mar 01; 29(3):183-6. PubMed ID: 18788619
    [Abstract] [Full Text] [Related]

  • 33. Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians.
    Nagi DK, Tracy R, Pratley R.
    Metabolism; 1996 Oct 01; 45(10):1243-7. PubMed ID: 8843179
    [Abstract] [Full Text] [Related]

  • 34. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease.
    Rattanawan C, Komanasin N, Settasatian N, Settasatian C, Kukongviriyapan U, Intharapetch P, Senthong V.
    Thromb Res; 2018 Nov 01; 171():171-176. PubMed ID: 30321704
    [Abstract] [Full Text] [Related]

  • 35. Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm.
    Dubis J, Zuk N, Grendziak R, Zapotoczny N, Pfanhauser M, Witkiewicz W.
    Blood Coagul Fibrinolysis; 2014 Apr 01; 25(3):226-31. PubMed ID: 24378973
    [Abstract] [Full Text] [Related]

  • 36. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
    Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J.
    J Thromb Haemost; 2007 Sep 01; 5(9):1862-8. PubMed ID: 17723126
    [Abstract] [Full Text] [Related]

  • 37. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody.
    Develter J, Booth NA, Declerck PJ, Gils A.
    J Thromb Haemost; 2008 Nov 01; 6(11):1884-91. PubMed ID: 18752580
    [Abstract] [Full Text] [Related]

  • 38. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors.
    Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC.
    Arterioscler Thromb Vasc Biol; 2000 Sep 01; 20(9):2156-61. PubMed ID: 10978263
    [Abstract] [Full Text] [Related]

  • 39. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation.
    Ząbczyk M, Majewski J, Lelakowski J.
    Pol Arch Med Wewn; 2011 Nov 01; 121(11):400-7. PubMed ID: 22064373
    [Abstract] [Full Text] [Related]

  • 40. Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index.
    de Mendonça-Louzeiro MR, Annichino-Bizzacchi JM, Benetti-Pinto CL.
    Fertil Steril; 2015 Aug 01; 104(2):467-73. PubMed ID: 26051101
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.